Project description:Caerin 1 is a family of host-defense peptides with antimicrobial property originally isolated from Australia tree frog. Caerin 1.1+1.9 has been shown to inhibit multiple antibiotic resistant bacteria infection both in vitro and in vivo. In current study, we compare the MICs of caerin 1.1/1.9 with commonly used antibiotics against S. aureus, Copper-Green Pseudomonas aeruginosa, Acinetobacter baumannii, and Streptococcus haemolyticus. We demonstrate that caerin 1.1/1.9 not only prevent the formation of biofilm by A. Baumann, but also have therapeutic effect on established biofilm. In addition, we find that caerin1.1/1.9 significantly inhibit the growth of methicillin-resistant Staphylococcus aureus (MRSA) strain in a murine skin infection model. The quantitative proteomic analysis suggested that caerin1.1/1.9 largely activate oxidative phosphorylation, as well as several pathways associated with tissue repair and growth, with respect to the untreated tissues infected with MRSA in mice. In summary, our results suggest that caerin 1.1/1.9 have the potential to be used as a drug candidate treating complicated antibiotic resistant bacterial infection in human.
Project description:Glioblastoma, the most aggressive form of brain cancer, remains a significant global contributor to mortality. Predictions of its increasing incidence in the coming decades underscore the need for more effective treatment strategies. Caerin 1.1 and 1.9, host defence peptides originally isolated from the skin secretions of an Australian tree frog, have exhibited tumour growth inhibition against a diverse spectrum of tumours in vitro. In this study, we reaffirm their potential by demonstrating their inhibitory impact on glioblastoma growth through CCK8 assays. Furthermore, caerin 1.1 and 1.9 effectively curtailed the migration of all tested glioblastoma cells in a cell scratch assay.Quantitative proteomic analysis was employed to investigate the molecular mechanism underlying the anti-proliferative activity.
Project description:Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with anti-EGFR in combination with chemotherapy.
| 2267065 | ecrin-mdr-crc
Project description:microbial diversity of frog SKIN
| PRJNA509098 | ENA
Project description:microbial diversity of frog SKIN
